Gilead Sciences, Inc
SWB:GIS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Gilead Sciences, Inc (GIS) under the Base Case is EUR per share.
Compared with the current market price of 151.66 EUR, the stock appears .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
What one share is worth in the bear, base and bull cases.
Create a free account · No card needed
Do our valuations actually work? See backtest results .
Intrinsic value next to the price over the past 5 years, and what happened after valuations like today’s.
Create a free account · No card needed
Fundamental Analysis
What Gilead Sciences Does
Gilead Sciences is a biopharmaceutical company that develops and sells prescription medicines, especially in antiviral treatments. Its best-known products have been used to treat HIV, hepatitis B and C, and it also sells medicines for cancer and inflammatory diseases. The company focuses on discovering drugs, testing them in clinical trials, getting them approved, and then manufacturing and marketing them to patients who need long-term treatment.
- Headquarters
- United States of America US
- Employees
- 17 000
- IPO date
- Jan 22, 1992
Gilead Sciences has a wide economic moat
Patents keep rivals from copying important Gilead medicines such as Biktarvy, allowing the company to earn profits from treatments competitors cannot freely reproduce. The medical review needed to change a successful HIV treatment also helps protect its established patient base, particularly when drug resistance limits alternatives.
Read the full moat analysis
Revenue & Expenses Breakdown
Gilead Sciences, Inc
Earnings Waterfall
Gilead Sciences, Inc
What is the Intrinsic Value of one GIS stock?
The intrinsic value for Gilead Sciences, Inc (GIS) under the Base Case is EUR.
Is GIS stock undervalued or overvalued?
Compared with the current market price of 151.66 EUR, the stock appears .
